Close Menu

NEW YORK – For the past month, engineering biology firm Sherlock Biosciences has been developing and testing a series of assays for SARS-CoV-2, the pathogen that causes coronavirus disease 2019 (COVID-19). Now, the company believes it is almost ready to release what will likely be the first CRISPR-based diagnostic test for the virus, and is in talks with a variety of possible partners in the US and China to deploy it at a large scale.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.